Abbott Laboratories is rated a strong buy due to its undervaluation and solid fundamentals despite recent price drops. Trading at a significant discount to peers, the company's value is supported by growth drivers like the Exact Sciences acquisition and expansion in continuous glucose monitoring globally. Analysts have raised full-year 2026 sales and earnings guidance, with average price targets suggesting up to 39.4% upside. This outlook indicates potential for Abbott to be re-rated higher by the market.
Abbott's board announced a quarterly dividend of 63 cents per share, marking the company's 410th consecutive quarterly dividend since 1924. This consistent dividend payment underscores Abbott's long-standing commitment to returning value to sharehold...
Abbott's board announced a quarterly dividend of 63 cents per share, payable on August 17, 2026, to shareholders of record as of July 15, 2026. This dividend marks Abbott's 410th consecutive quarterly payout since 1924 and continues its streak of 54 ...
A study presented at the American Diabetes Association's Scientific Sessions found that Abbott's Healthy Food Rx program, which provides recipe-based food boxes and health coaching to adults with type 2 diabetes, significantly improved participants' ...
